Hiroshi Sasaki

Hiroshi Sasaki

Auto-generated profile, based on publicly available information

Hiroshi Sasaki

Department of Urology The Jikei University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SKShoji Kimura
Shoji Kimura
Fumihiko UrabeFumihiko Urabe
Fumihiko Urabe
HSHiroshi Sasaki
Hiroshi Sasaki
TKTakahiro Kimura
Takahiro Kimura
KMKenta Miki
Kenta Miki
SEShin Egawa
Shin Egawa
We performed a systematic review and meta-analysis to assess the prognostic value of prostate-specific antigen (PSA) persistence 4–8 weeks after radical prostatectomy (RP) in patients with prostate cancer, using studies from Medline, Scopus, and Cochrane Library, on 10 October 2020. Studies were eligible if they compared patients with postoperative PSA persistence 4–8 weeks after RP to those without such persistence to assess the value of PSA persistence in prognosticating biochemical recurrence (BCR), disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM) by multivariable analysis. Our review and analysis included nine studies published between 2008 and 2019 with 14,455 patients. Of those studies, 12.0% showed postoperative PSA persistence. PSA persistence was associated with BCR (HR: 4.44, 95% CI: 2.84–6.93), disease recurrence (HR: 3.43, 95% CI: 1.62–7.25), and CSM (HR: 2.32, 95% CI: 1.83–2.95). We omitted meta-analysis on the association of PSA persistence with OM due to an insufficient number of studies. PSA persistence was associated with disease recurrence in a sub-group of patients with pathological nodal involvement (HR: 5.90, 95% CI: 3.76–9.24). Understanding detection of PSA persistence at 4–8 weeks after RP might be useful for patient counseling, follow-up scheduling, and clinical decision-making regarding adjuvant therapies.

21 October 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKenta Miki
Kenta Miki
TKTakayoshi Kiba
Takayoshi Kiba
HSHiroshi Sasaki
Hiroshi Sasaki
MKMasahito Kido
Masahito Kido
MAManabu Aoki
Manabu Aoki
SEShin Egawa
Shin Egawa
Background: The optimal protocol for 125I-transperineal prostatic brachytherapy (TPPB) in intermediate-risk prostate cancer (PCa) patients remains controversial. Data on the efficacy of combining androgen-deprivation therapy (ADT) with 125I-TPPB in this group remain limited and consequently the guidelines of the American Brachytherapy Society (ABS) provide no firm recommendations. Methods/Design: Seed and Hormone for Intermediate-risk Prostate Cancer (SHIP) 0804 is a phase III, multicenter, randomized, controlled study that will investigate the impact of adjuvant ADT following neoadjuvant ADT and 125I-TPPB. Prior to the end of March, 2011, a total of 420 patients with intermediate-risk, localized PCa will be enrolled and randomized to one of two treatment arms. These patients will be recruited from 20 institutions, all of which have broad experience of 125I-TPPB. Pathological slides will be centrally reviewed to confirm patient eligibility. The patients will initially undergo 3-month ADT prior to 125I-TPPB. Those randomly assigned to adjuvant therapy will subsequently undergo 9 months of adjuvant ADT. All participants will be assessed at baseline and at the following intervals: every 3 months for the first 24 months following 125I-TPPB, every 6 months during the 24- to 60-month post-125I-TPPB interval, annually between 60 and 84 months post-125I-TPPB, and on the 10th anniversary of treatment. The primary endpoint is biochemical progression-free survival (BPFS). Secondary endpoints are overall survival (OS), clinical progression-free survival, disease-specific survival, salvage therapy non-adaptive interval, acceptability (assessed using the international prostate symptom score [IPSS]), quality of life (QOL) evaluation, and adverse events. In the correlative study (SHIP36B), we also evaluate biopsy results at 36 months following treatment to examine the relationship between the results and the eventual recurrence after completion of radiotherapy. Discussion: These two multicenter trials (SHIP0804 & SHIP36B) are expected to provide crucial data regarding the efficacy, acceptability and safety of adjuvant ADT. SHIP36B will also provide important information about the prognostic implications of PSA levels in intermediate-risk PCa patients treated with 125I-TPPB. Trial registration: NCT00664456, NCT00898326, JUSMH-BRI-GU05-01, JUSMH-TRIGU0709

23 December 2013 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
HSHiroshi Sasaki
Hiroshi Sasaki
MKMasahito Kido
Masahito Kido
KMKenta Miki
Kenta Miki
HKHidetoshi Kuruma
Hidetoshi Kuruma
HTHiroyuki Takahashi
Hiroyuki Takahashi
SEShin Egawa
Shin Egawa
Objectives: To characterize local recurrence of prostate cancer and to assess the effect of salvage partial brachytherapy after primary 125‐iodine low‐dose rate brachytherapy with or without external beam radiotherapy in Japanese men.Methods: Between 2003 and 2010, a total of 616 consecutive patients underwent low‐dose rate brachytherapy‐based therapy for clinically localized prostate cancer at Jikei University Hospital in Tokyo, Japan. Biochemical recurrence occurred in 45 (7.3%) patients at a median of 30 months (range 11–93 months). A total of 20 patients subsequently underwent transperineal template prostatic biopsy; of those, eight had positive cores at the base of the prostate or at the seminal vesicles. These eight patients had underdosed areas identified at initial low‐dose rate brachytherapy corresponding to the positive biopsy sites. All were confirmed to have only localized recurrence, and seven underwent salvage partial low‐dose rate brachytherapy.Results: Median prostate‐specific antigen nadir level in the eight patients with biopsy‐proven local recurrence after initial low‐dose rate brachytherapy was 0.75 ng/mL (range 0.39–2.06). The seven retreated patients tolerated the salvage partial low‐dose rate brachytherapy well, and showed a decrease in prostate‐specific antigen level at follow up. Two patients later developed biochemical and clinical progression at 11 and 13 months, respectively. Prostate‐specific antigen level continued to be low in the remaining five patients. No significant genitourinary or gastrointestinal toxicity was encountered.Conclusions: Salvage partial low‐dose rate brachytherapy for biopsy‐proven localized prostate cancer recurrence appears rational, technically feasible and safe. Optimal patient selection is of utmost importance for long‐term success. Larger studies with longer follow up are warranted.

1 November 1997 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
THToshiro Hayashida
Toshiro Hayashida
PEPamela Eversole-Cire
Pamela Eversole-Cire
PJPeter A. Jones
Peter A. Jones
HSHiroyuki Sasaki
Hiroyuki Sasaki
It was previously reported that the imprinted insulin-like growth factor II and H19 genes are up-regulated in embryonic fibroblasts upon growth arrest. We have examined six other imprinted genes and found that all were up-regulated upon confluency and at least four of them by serum starvation. The significance of the results was confirmed by demonstrating that only one-third of randomly selected genes are up-regulated upon confluency. Our findings suggest that the cell cycle should be carefully controlled when imprinted genes are studied in cell cultures. Moreover, the unique property could have significance in the mechanistic or the evolutionary aspect of imprinting or both.

4 May 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
Fumihiko UrabeFumihiko Urabe
Fumihiko Urabe
SKShoji Kimura
Shoji Kimura
KTKojiro Tashiro
Kojiro Tashiro
MKMasahito Kido
Masahito Kido
HSHiroshi Sasaki
Hiroshi Sasaki
SEShin Egawa
Shin Egawa

29 July 2009 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
HSHiroshi Sasaki
Hiroshi Sasaki
JMJun Miki
Jun Miki
TKTakahiro Kimura
Takahiro Kimura
KSKunitaro Sanuki
Kunitaro Sanuki
KMKenta Miki
Kenta Miki
SEShin Egawa
Shin Egawa